Comparative Pharmacology
Head-to-head clinical analysis: ABSORICA LD versus TAZAROTENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABSORICA LD versus TAZAROTENE.
ABSORICA LD vs TAZAROTENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoid that reduces sebum production, normalizes follicular keratinization, and inhibits Propionibacterium acnes growth via modulation of gene expression.
Tazarotene is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity, modulating gene expression involved in cell proliferation, differentiation, and inflammation.
0.5-1 mg/kg/day orally divided twice daily for 4-5 months, max 2 mg/kg/day.
Topical: Apply a pea-sized amount to affected areas once daily in the evening. For plaque psoriasis, use 0.05% or 0.1% gel or cream. For acne vulgaris, use 0.1% cream or 0.045% or 0.1% lotion.
None Documented
None Documented
Clinical Note
moderateTazarotene + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Tazarotene."
Clinical Note
moderateTazarotene + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Tazarotene."
Clinical Note
moderateTazarotene + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Tazarotene."
Clinical Note
moderateTazarotene + Nilotinib
Terminal elimination half-life is 21 hours (range 7–39 hours) for isotretinoin. Clinical context: Steady-state achieved after 5–7 days of dosing.
Terminal elimination half-life of tazarotenic acid is 7–12 hours in healthy subjects; clinically, steady-state is achieved within 14 days.
Primarily renal, 65% as unchanged drug; 35% as metabolites. Fecal elimination accounts for less than 5%.
Primarily fecal (approximately 60%) and urinary (approximately 13%) as metabolites; unchanged drug not detected in urine.
Category C
Category D/X
Retinoid
Retinoid
"The metabolism of Nilotinib can be decreased when combined with Tazarotene."